Corcept Therapeutics Incorporated (CORT) on Thursday said its pivotal Phase 3 ROSELLA trial of relacorilant in combination with chemotherapy drug nab-paclitaxel met its primary endpoint of overall survival in patients with platinum-resistant ovarian cancer. Following the announcement, the company's shares rose more than 25% in premarket trading.
In the ROSELLA trial, patients treated with relacorilant plus nab-paclitaxel showed a 35% reduction in the risk of death compared with those receiving nab-paclitaxel alone. Median overall survival was 16 months for patients in the combination arm, versus 11.9 months for those treated with nab-paclitaxel alone.
The combination therapy was well tolerated, with the type, frequency, and severity of adverse events being comparable to those observed in the nab-paclitaxel monotherapy arm.
Corcept had previously announced that the ROSELLA trial also met its primary endpoint of improved progression-free survival.
The company is currently studying relacorilant in other solid tumors, including platinum-sensitive ovarian, endometrial, cervical, pancreatic and prostate cancers.
On Wednesday, Corcept's shares closed at $36.31, up 2.89%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.